Accuray Receives Outstanding Innovative Improvement Award for its CyberKnife System
SUNNYVALE, Calif., Nov. 30, 2011 /PRNewswire/ — Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, today announced that the company received the Outstanding Innovative Improvement Award for its CyberKnifeÃ‚® Robotic Radiosurgery System at the 3rd Annual Employer Healthcare Congress, which took place October 25 – 28, 2011 in Chicago.
The award was presented to Accuray in recognition of the fact that patients treated with the CyberKnife System are able to complete treatment in five days or less, compared to radiation therapy treatments, which typically require up to 40 treatment sessions. This significant reduction in the number of daily treatments helps patients get back to work faster, benefitting employees and employers alike. The CyberKnife System targets tumors anywhere in the body and delivers high doses of radiation with pinpoint accuracy. Unlike any other radiation delivery system, the CyberKnife System tracks and adjusts treatment delivery to compensate for tumor motion, including respiration.
“Treatment with the CyberKnife System is typically completed in five or fewer outpatient sessions, compared to the six weeks of daily treatments typical with conventional radiation. Fewer daily treatments allow the employee to get back to their normal schedule, including work, resulting in less stress for the employee and a more efficient workplace for the employer,” said Jonathan Edelheit, president of the Employer Healthcare Congress. “Accuray has made a tremendous effort to ensure that employees are aware of the full range of options so they can make an informed treatment decision. We wanted to recognize Accuray’s innovative technology, as well as its education efforts with this award.”
The Employer Healthcare Congress is among the largest healthcare conferences in the United States. One of the major highlights of the conference is the Leadership Awards given for both excellence in Corporate Wellness and Voluntary Benefits. The Outstanding Innovative Improvement Award honors a company that not only has brought a healthy innovation to employees, but also a cutting-edge approach to changing the way we deal with chronic illness and critical care, all while helping employers reduce healthcare costs.
“Accuray is honored to receive this award from the Employer Healthcare Congress recognizing the advantages that the CyberKnife System offers not only to employees, but employers as well,” said Euan S. Thomson, Ph.D., president and chief executive officer of Accuray. “This award reaffirms our commitment to developing personalized, leading-edge treatment solutions that help cancer patients live longer, better lives. This means not only treating their tumors, but also helping them return to their normal lives as soon as possible.”
Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is the premier radiation oncology company that develops, manufactures and sells personalized innovative treatment solutions that set the standard of care, with the aim of helping patients live longer, better lives. The Company’s leading edge technologies – the CyberKnife and TomoTherapy Systems – are designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy, and adaptive radiation therapy. To date, more than 200,000 patients worldwide have been treated using the Company’s technologies and more than 598 systems have been installed in leading hospitals around the world. For more information, please visit www.accuray.com.
Safe Harbor Statement
The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, including statements relating to patient experience and employee & employer benefits are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management’s good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: clinical effectiveness, range of treatment options, clinical applications, and market acceptance of products and other risks detailed from time to time under the heading “Risk Factors” in our report on Form 10-K for our 2011 fiscal year, our form 10-Q filed on November 8, 2011 and our other filings with the Securities and Exchange Commission. The Company’s actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.
SOURCE Accuray Incorporated